Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

0503586 - BTÚ 2019 RIV US eng J - Článek v odborném periodiku
Piggott, L. - Silva, A. - Robinson, T. - Santiago-Gomez, A. - Simoes, B. M. - Becker, M. - Fichtner, I. - Anděra, Ladislav - Young, P. - Morris, Ch. - Barrett-Lee, P. - Alchami, F. - Piva, M. - Vivanco, M. D. - Clarke, R. B. - Gee, J. - Clarkson, R.
Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
Clinical Cancer Research. Roč. 24, č. 10 (2018), s. 2452-2463. ISSN 1078-0432. E-ISSN 1557-3265
Institucionální podpora: RVO:86652036
Klíčová slova: FLICE inhibitory protein recombinant tumor necrosis factor related apoptosis inducing ligand * fulvestrant * recombinant tumor necrosis factor related apoptosis inducing ligand
Obor OECD: Oncology
Impakt faktor: 8.911, rok: 2018

Purpose: One third of ER-positive breast cancer patients who initially respond to endocrine therapy become resistant to treatment. Such treatment failure is associated with poor prognosis and remains an area of unmet clinical need. Here, we identify a specific posttranslational modification that occurs during endocrine resistance and which results in tumor susceptibility to the apoptosis-inducer TRAIL. This potentially offers a novel stratified approach to targeting endocrine-resistant breast cancer.
Trvalý link: http://hdl.handle.net/11104/0295402